Developer docs
API playgroundTry for free, no card

Search company profiles

Cellular Intelligence

Full company profile

uuid0000amd

Namestring
Cellular Intelligence
Legal namestring
Somite Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Cellular Intelligence (legal entity: Somite Therapeutics, Inc.) is a Boston-based AI-native TechBio company building what it describes as the first universal virtual cell-signaling foundation model — a transformer-based architecture trained to predict how any human cell, in any state, will respond to external biological signals. The company was founded in 2023 as Somite by repeat AI entrepreneur Micha Breakstone (previously sold Chorus.ai for $575M), MIT's Jonathan Rosenfeld, and four scientific co-founders from Harvard Medical School and the University of Washington. Its core technology stack comprises a proprietary capsule-based split-and-pool data generation platform that produces context-rich perturbation data at roughly 1,000x the efficiency and ~1/1000th the cost of conventional methods, the DeltaStem foundation model for cell differentiation, and an active-learning loop that prioritizes its own experiments. The platform has scaled from 27,000 to over one million unique signal combinations, using human stem cells across thousands of developmental contexts rather than cancer cell lines, to preserve physiological relevance.

The company's go-to-market is a hybrid platform-plus-therapeutics model. On the platform side, it offers co-development, licensing, and platform access to pharmaceutical partners seeking to compress cell therapy development timelines; Novo Nordisk is the first disclosed strategic partner following its May 2026 sale of the STEM-PD Parkinson's program to Cellular Intelligence alongside an equity investment. On the therapeutics side, the company acquired and now controls STEM-PD — a Phase 2-ready, FDA Fast Track-designated allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy for Parkinson's disease originating from University of Cambridge and Lund University research — with pipeline expansion signaled into type 1 diabetes (beta cells), orthopedics (cartilage), and Duchenne muscular dystrophy (satellite cells). Revenue is expected to flow through platform licensing/royalties and clinical milestones/royalties from co-developed programs, though the company remains pre-commercial with no approved products. Operations are anchored in Boston with a translational laboratory in Copenhagen, an 11–50 person team, and cumulative funding of over $62M from Khosla Ventures, the Chan Zuckerberg Initiative, AMD Ventures, SciFi VC, Fusion Fund, Novo Nordisk, and others.

Short descriptiontext

Cellular Intelligence is a Boston-based AI-native TechBio company building a universal virtual cell-signaling foundation model and a proprietary capsule-based data platform to rationally design cell differentiation protocols, with a Phase 2-ready Parkinson's cell therapy (STEM-PD) and pipeline expansion into diabetes, orthopedics, and muscular dystrophy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI foundation models, cell therapy platform, regenerative medicine AI, computational biology tools, drug discovery platform
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
AI Drug Discovery Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Licensing and Co-development
TypeLicensing Royalties
Description

Revenue expected through licensing the AI platform to pharmaceutical partners for cell therapy development and manufacturing optimization. The company applies its AI-native platform to accelerate programs, with clinical and manufacturing data generated further training the foundation model for broader applications.

biospace.com
2Milestone and Royalty Payments from STEM-PD
TypeLicensing Royalties
Description

Novo Nordisk will receive milestone payments and royalties if the STEM-PD program succeeds. This represents a potential future revenue stream through successful clinical development and commercialization of acquired or co-developed cell therapy programs.

biospace.com
3Therapeutic Development
TypeLicensing Royalties
Description

Development and commercialization of proprietary cell therapy programs including STEM-PD for Parkinson's disease and future pipeline candidates in type 1 diabetes, orthopedics, and muscular diseases.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Cellular Intelligence develops AI-driven foundation models and platforms to predict and control cell behavior for regenerative medicine. Its core offerings include the Universal Virtual Cell-Signaling Model and DeltaStem foundation models, supported by a proprietary capsule-based data generation platform that produces perturbation data at approximately 1,000x the efficiency of traditional methods. The company applies this platform to advance proprietary cell therapy programs, including the Phase 2-ready STEM-PD therapy for Parkinson's disease acquired from Novo Nordisk, while offering platform access, co-development, and licensing arrangements to pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 1,000x higher efficiency in data generation compared to conventional methods
+2 more records
Product overview1 text field

Cellular Intelligence is an AI-native TechBio company operating under the legal entity Somite Therapeutics, building the first universal virtual cell-signaling model to decode and control cellular behavior. The core technology stack comprises the proprietary Capsule-Based Platform for high-throughput data generation (1,000x more efficient than existing methods), the DeltaStem foundation model for predicting cell differentiation, and the Universal Virtual Cell-Signaling Model as the overarching AI engine. The company is applying this platform to advance STEM-PD, a clinical-stage allogeneic cell therapy for Parkinson's disease acquired from Novo Nordisk in May 2026. The platform enables rational protocol design for regenerative medicine by replacing empirical trial-and-error with in silico prediction.

Product and service4 records
1DeltaStem
CategoryFoundation Model / Software
Description

A foundation model designed to produce any cell type for any person by learning the combinatorial signaling logic that determines cellular behavior. The model accelerates discovery of new cell differentiation protocols and optimizes them for purity, functionality, and scalability. It is intended for pharmaceutical partners and internal therapeutic programs.

2STEM-PD
CategoryCell Therapy / Therapeutic Product
Description

Allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy for Parkinson's disease, designed to replace the dopaminergic neurons lost to the disease rather than only manage symptoms. Phase 2-ready with FDA Fast Track Designation and IND clearance, intended for patients with Parkinson's disease.

3Capsule-Based Platform
CategoryData Generation Platform / Software & Wet-Lab
Description

Proprietary data generation platform using split-and-pool capsule technology with unique barcoding methodology, enabling interrogation of exponentially expanding sets of signaling factor combinations and cell states. Generates massive, context-rich datasets at approximately 1,000x the efficiency of existing methods, covering millions of unique perturbation conditions per experiment. Intended for pharmaceutical partners and internal therapeutic programs.

4Universal Virtual Cell-Signaling Model
CategoryFoundation Model / Software
Description

Foundation model that predicts how any cell in any state changes in response to external signals, acting as a computational twin of living cells. Decodes the grammar of cellular signaling and transforms biology from empirical trial-and-error into predictive engineering, enabling rational protocol design for regenerative medicine and context-specific drug effect prediction. Built on transformer architectures with Neural ODEs for continuous-time dynamics.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-11
Description

Cellular Intelligence acquired global rights to Novo Nordisk's STEM-PD clinical-stage cell therapy program for Parkinson's disease. Novo Nordisk made a strategic equity investment in Cellular Intelligence and will receive future milestone payments and royalties if the program succeeds. This deal catapults CI into a Phase 2-ready clinical company.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

STEM-PD began as a research collaboration between University of Cambridge and Lund University, two of the world's leading centers for Parkinson's research. The academic clinical trial was funded by Novo Nordisk and is the foundation of the current program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

STEM-PD originated from research collaboration between Lund University and University of Cambridge. Lund's foundational work in Parkinson's research contributed to the development of the allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellular Intelligence

AI Drug Discovery Platformcellularintelligence.com

Cellular Intelligence is a Boston-based AI-native TechBio company building a universal virtual cell-signaling foundation model and a proprietary capsule-based data platform to rationally design cell differentiation protocols, with a Phase 2-ready Parkinson's cell therapy (STEM-PD) and pipeline expansion into diabetes, orthopedics, and muscular dystrophy.

What Cellular Intelligence does

Cellular Intelligence (legal entity: Somite Therapeutics, Inc.) is a Boston-based AI-native TechBio company building what it describes as the first universal virtual cell-signaling foundation model — a transformer-based architecture trained to predict how any human cell, in any state, will respond to external biological signals. The company was founded in 2023 as Somite by repeat AI entrepreneur Micha Breakstone (previously sold Chorus.ai for $575M), MIT's Jonathan Rosenfeld, and four scientific co-founders from Harvard Medical School and the University of Washington. Its core technology stack comprises a proprietary capsule-based split-and-pool data generation platform that produces context-rich perturbation data at roughly 1,000x the efficiency and ~1/1000th the cost of conventional methods, the DeltaStem foundation model for cell differentiation, and an active-learning loop that prioritizes its own experiments. The platform has scaled from 27,000 to over one million unique signal combinations, using human stem cells across thousands of developmental contexts rather than cancer cell lines, to preserve physiological relevance.

The company's go-to-market is a hybrid platform-plus-therapeutics model. On the platform side, it offers co-development, licensing, and platform access to pharmaceutical partners seeking to compress cell therapy development timelines; Novo Nordisk is the first disclosed strategic partner following its May 2026 sale of the STEM-PD Parkinson's program to Cellular Intelligence alongside an equity investment. On the therapeutics side, the company acquired and now controls STEM-PD — a Phase 2-ready, FDA Fast Track-designated allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy for Parkinson's disease originating from University of Cambridge and Lund University research — with pipeline expansion signaled into type 1 diabetes (beta cells), orthopedics (cartilage), and Duchenne muscular dystrophy (satellite cells). Revenue is expected to flow through platform licensing/royalties and clinical milestones/royalties from co-developed programs, though the company remains pre-commercial with no approved products. Operations are anchored in Boston with a translational laboratory in Copenhagen, an 11–50 person team, and cumulative funding of over $62M from Khosla Ventures, the Chan Zuckerberg Initiative, AMD Ventures, SciFi VC, Fusion Fund, Novo Nordisk, and others.

Cellular Intelligence firmographics

Firmographics
Name
Cellular Intelligence
Legal name
Somite Therapeutics, Inc.
Website
https://cellularintelligence.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
Cellular Intelligence is a Boston-based AI-native TechBio company building a universal virtual cell-signaling foundation model and a proprietary capsule-based data platform to rationally design cell differentiation protocols, with a Phase 2-ready Parkinson's cell therapy (STEM-PD) and pipeline expansion into diabetes, orthopedics, and muscular dystrophy.
Ownership category
akta.pro rank

Cellular Intelligence industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI foundation models
  • Cell therapy platform
  • Regenerative medicine AI
  • Computational biology tools
  • Drug discovery platform

Where Cellular Intelligence is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cellular Intelligence business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Platform Licensing and Co-development: Revenue expected through licensing the AI platform to pharmaceutical partners for cell therapy development and manufacturing optimization. The company applies its AI-native platform to accelerate programs, with clinical and manufacturing data generated further training the foundation model for broader applications.
  2. Milestone and Royalty Payments from STEM-PD: Novo Nordisk will receive milestone payments and royalties if the STEM-PD program succeeds. This represents a potential future revenue stream through successful clinical development and commercialization of acquired or co-developed cell therapy programs.
  3. Therapeutic Development: Development and commercialization of proprietary cell therapy programs including STEM-PD for Parkinson's disease and future pipeline candidates in type 1 diabetes, orthopedics, and muscular diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Cellular Intelligence product offering

Product offering

Core offering

Cellular Intelligence develops AI-driven foundation models and platforms to predict and control cell behavior for regenerative medicine. Its core offerings include the Universal Virtual Cell-Signaling Model and DeltaStem foundation models, supported by a proprietary capsule-based data generation platform that produces perturbation data at approximately 1,000x the efficiency of traditional methods. The company applies this platform to advance proprietary cell therapy programs, including the Phase 2-ready STEM-PD therapy for Parkinson's disease acquired from Novo Nordisk, while offering platform access, co-development, and licensing arrangements to pharmaceutical partners.

Product overview

Cellular Intelligence is an AI-native TechBio company operating under the legal entity Somite Therapeutics, building the first universal virtual cell-signaling model to decode and control cellular behavior. The core technology stack comprises the proprietary Capsule-Based Platform for high-throughput data generation (1,000x more efficient than existing methods), the DeltaStem foundation model for predicting cell differentiation, and the Universal Virtual Cell-Signaling Model as the overarching AI engine. The company is applying this platform to advance STEM-PD, a clinical-stage allogeneic cell therapy for Parkinson's disease acquired from Novo Nordisk in May 2026. The platform enables rational protocol design for regenerative medicine by replacing empirical trial-and-error with in silico prediction.

Differentiator

Problem solved

Functional benefit

Products and services

  • DeltaStem A foundation model designed to produce any cell type for any person by learning the combinatorial signaling logic that determines cellular behavior. The model accelerates discovery of new cell differentiation protocols and optimizes them for purity, functionality, and scalability. It is intended for pharmaceutical partners and internal therapeutic programs.
  • STEM-PD Allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy for Parkinson's disease, designed to replace the dopaminergic neurons lost to the disease rather than only manage symptoms. Phase 2-ready with FDA Fast Track Designation and IND clearance, intended for patients with Parkinson's disease.
  • Capsule-Based Platform Proprietary data generation platform using split-and-pool capsule technology with unique barcoding methodology, enabling interrogation of exponentially expanding sets of signaling factor combinations and cell states. Generates massive, context-rich datasets at approximately 1,000x the efficiency of existing methods, covering millions of unique perturbation conditions per experiment. Intended for pharmaceutical partners and internal therapeutic programs.
  • Universal Virtual Cell-Signaling Model Foundation model that predicts how any cell in any state changes in response to external signals, acting as a computational twin of living cells. Decodes the grammar of cellular signaling and transforms biology from empirical trial-and-error into predictive engineering, enabling rational protocol design for regenerative medicine and context-specific drug effect prediction. Built on transformer architectures with Neural ODEs for continuous-time dynamics.

Quantifiable outcome

  • 1,000x higher efficiency in data generation compared to conventional methods
  • +2 more outcomes

Companies that use Cellular Intelligence

Customer profile

Segments2 records

Ideal customer profiles2 records

Cellular Intelligence technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Cellular Intelligence partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Novo NordiskcoreStrategic or Co-development Partner · 11 May 2026Cellular Intelligence acquired global rights to Novo Nordisk's STEM-PD clinical-stage cell therapy program for Parkinson's disease. Novo Nordisk made a strategic equity investment in Cellular Intelligence and will receive future milestone payments and royalties if the program succeeds. This deal catapults CI into a Phase 2-ready clinical company.
  • University of CambridgecoreStrategic or Co-development PartnerSTEM-PD began as a research collaboration between University of Cambridge and Lund University, two of the world's leading centers for Parkinson's research. The academic clinical trial was funded by Novo Nordisk and is the foundation of the current program.
  • Lund UniversitycoreStrategic or Co-development PartnerSTEM-PD originated from research collaboration between Lund University and University of Cambridge. Lund's foundational work in Parkinson's research contributed to the development of the allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Cellular Intelligence competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cellular Intelligence social profiles

Digital presence

Cellular Intelligence financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellular Intelligence leadership team

Management profile

Number of profiles

Profiles8 records

Cellular Intelligence funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellular Intelligence M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellular Intelligence

What does Cellular Intelligence do?

Cellular Intelligence develops AI-driven foundation models and platforms to predict and control cell behavior for regenerative medicine. Its core offerings include the Universal Virtual Cell-Signaling Model and DeltaStem foundation models, supported by a proprietary capsule-based data generation platform that produces perturbation data at approximately 1,000x the efficiency of traditional methods. The company applies this platform to advance proprietary cell therapy programs, including the Phase 2-ready STEM-PD therapy for Parkinson's disease acquired from Novo Nordisk, while offering platform access, co-development, and licensing arrangements to pharmaceutical partners.

Is Cellular Intelligence a public or private company?

Cellular Intelligence is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cellular Intelligence founded?

Cellular Intelligence was founded in 2023. It employs 51 to 100 people.

Where is Cellular Intelligence based?

Cellular Intelligence is headquartered in Boston, United States, in the North America region.

How does Cellular Intelligence make money?

Three revenue lines are on record. Platform Licensing and Co-development is the primary driver. The others are milestone and Royalty Payments from STEM-PD and therapeutic Development.

Does Cellular Intelligence have an API?

No public API is recorded for Cellular Intelligence.

What industry is Cellular Intelligence in?

Cellular Intelligence's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Naver파킨슨병 신약 ‘새판’…얀 르쿤·SK바이오팜도 뛰어들었다Cellular, a new company, plans to use AI for developing a Parkinson's drug targeting alpha-synuclein, with a Phase 2 trial expected in 2027. SK Biopharm has acquired a dual-target compound from First Biotherapeutics, and both companies are advancing Parkinson's treatments beyond dopamine replacement.PR NewswireYann LeCun, Bob Langer, Jens Nielsen and Fabian Theis Join Cellular Intelligence Scientific Advisory BoardCellular Intelligence announced that Yann LeCun, Bob Langer, Jens Nielsen, and Fabian Theis joined its Scientific Advisory Board. The four hold a Turing Award, over 1,500 patents, and founded Moderna, with Langer joining as a board observer. Their expertise targets learning predictive models from complex systems and applying them to therapeutic development.Crypto BriefingModerna’s Bob Langer and Yann LeCun join Cellular Intelligence advisory board to advance AI in medicineModerna's Bob Langer and Yann LeCun joined Cellular Intelligence's advisory board, with Langer also joining as an observer. The Boston startup, backed by $62M+ in funding, is building a foundation model for cell behavior and has a Parkinson's therapy ready for Phase 2 trials.FortuneModerna's Bob Langer and AMI's Yann LeCun Cellular Intelligence's board, bringing AI into medicineModerna co-founder Bob Langer and AI researcher Yann LeCun joined Cellular Intelligence's scientific advisory board, along with Jens Nielsen and Fabian Theis. The company aims to use AI to predict and control living cells, with a Parkinson's drug in Phase 2. It plans to license its models to pharma partners and develop additional medicines.MorningstarYann LeCun, Bob Langer, Jens Nielsen and Fabian Theis Join Cellular Intelligence Scientific Advisory BoardCellular Intelligence announced that Yann LeCun, Bob Langer, Jens Nielsen, and Fabian Theis joined its Scientific Advisory Board. The four hold a Turing Award, over 1,500 patents, and founded Moderna, with Langer joining as a board observer. Their expertise supports the company's goal of building a universal foundation model of cell signaling.The Times of IndiaTOI Bharat Abroad: Trump’s birth tourism task force & biology’s next big leapThe Trump administration has established a Birth Tourism Prevention Task Force and proposed new restrictions on F-1 students and H-1B workers, intensifying scrutiny on visa holders. In the biotech sector, University of Pennsylvania professor Arjun Raj joined Cellular Intelligence as chief scientific officer to develop AI models for cellular prediction, following the company's acquisition of a Parkinson’s therapy from Novo Nordisk. Additionally, three US states—Delaware, New York, and New Jersey—have issued official proclamations recognizing India’s 80th Independence Day.The Times of IndiaAI biotech company Cellular Intelligence names Arjun Raj its chief scientific officerCellular Intelligence has appointed Arjun Raj as its chief scientific officer and scientific co-founder to lead the company's overall scientific strategy for developing a universal foundation model of cell signalling. This appointment follows the company's acquisition of a Parkinson's disease cell therapy programme from Novo Nordisk in May, which will serve as a proving ground for its AI-driven platform.PR NewswireCellular Intelligence Names Single-Cell Biology Pioneer Arjun Raj, Ph.D., Chief Scientific Officer and Scientific Co-FounderCellular Intelligence appointed Arjun Raj, Ph.D., as chief scientific officer and scientific co-founder. He will lead the company's closed-loop cell signaling platform, which includes its proprietary capsule-based platform and the recently acquired Parkinson's disease therapy STEM-PD.PR NewswireCellular Intelligence Expands Leadership Team with Seasoned AI and Biotech Industry ExecutivesCellular Intelligence appointed Jonathan Alspaugh as chief strategy officer and Adam Weinroth as chief marketing officer. The company also acquired STEM-PD, a Parkinson's disease cell therapy from Novo Nordisk, to advance its cell signaling foundation model.Endpoints NewsThe data that led Cellular Intelligence to pick up Novo’s Parkinson’s stem cell therapyCellular Intelligence, a Montreal-based AI biotech, contracted neurologist and drug developer Nuno Mendonça to conduct due diligence on Novo Nordisk's Parkinson's stem cell therapy after the Danish company closed its cell therapy unit. Following the due diligence review, Cellular Intelligence acquired the therapy asset. The article details the data and decision-making process behind this technology transfer in the cell and gene therapy space.